alfuzosin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihypertensive substances, prazosin derivatives 115 81403-80-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • alfuzosin
  • alfuzosin hydrochloride
  • xatral
  • SL 77
  • alfuzosin HCl
Alfuzosin is a selective antagonist of post-synaptic alpha1-adrenoreceptors, which are located in the prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra.
  • Molecular weight: 389.46
  • Formula: C19H27N5O4
  • CLOGP: 2.35
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 2
  • TPSA: 111.83
  • ALOGS: -3.14
  • ROTB: 8

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
7.50 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 11 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.34 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 55 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.50 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 5.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.14 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 4.80 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
June 12, 2003 FDA COVIS PHARMA SARL

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Apraxia 66.35 41.63 13 947 1532 50602632
Dementia 60.09 41.63 19 941 15978 50588186
Disorientation 52.14 41.63 21 939 35463 50568701
Perseveration 51.08 41.63 8 952 255 50603909

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug dispensed to wrong patient 142.99 13.51 33 17208 242 29557044
Acute kidney injury 119.61 13.51 382 16859 264885 29292401
Orthostatic hypotension 90.46 13.51 87 17154 22542 29534744
Syncope 81.11 13.51 159 17082 81212 29476074
Fall 76.69 13.51 252 16989 176926 29380360
Antimicrobial susceptibility test resistant 66.70 13.51 18 17223 264 29557022
Confusional state 66.51 13.51 194 17047 127683 29429603
Wrong patient received product 64.83 13.51 30 17211 2252 29555034
Cholestasis 64.72 13.51 74 17167 23388 29533898
Hepatocellular injury 63.73 13.51 70 17171 21173 29536113
Agranulocytosis 57.53 13.51 65 17176 20275 29537011
Therapeutic response delayed 54.11 13.51 17 17224 435 29556851
Toxicity to various agents 50.65 13.51 19 17222 173642 29383644
Thrombocytopenia 49.73 13.51 182 17059 134641 29422645
Hypotension 47.98 13.51 232 17009 194122 29363164
Urinary retention 46.89 13.51 74 17167 31824 29525462
Eosinophilia 43.59 13.51 59 17182 22102 29535184
Coma 40.35 13.51 78 17163 39372 29517914
Staring 38.77 13.51 18 17223 1361 29555925
Pemphigoid 37.79 13.51 33 17208 7548 29549738
Drug interaction 37.32 13.51 219 17022 197166 29360120
Allergy to animal 36.29 13.51 11 17230 249 29557037
Disorganised speech 36.24 13.51 14 17227 669 29556617
Product storage error 33.94 13.51 29 17212 6441 29550845
Cell death 32.07 13.51 18 17223 2026 29555260
Completed suicide 31.55 13.51 7 17234 90239 29467047
Daydreaming 29.63 13.51 11 17230 471 29556815
Brain stem haematoma 29.48 13.51 8 17233 120 29557166
Wrong product administered 29.43 13.51 23 17218 4508 29552778
Dermatitis exfoliative generalised 28.57 13.51 19 17222 2897 29554389
Nasal discomfort 28.52 13.51 14 17227 1198 29556088
Product dispensing error 27.61 13.51 24 17217 5456 29551830
Petit mal epilepsy 27.31 13.51 18 17223 2704 29554582
Minimum inhibitory concentration 25.99 13.51 6 17235 44 29557242
Blood thyroid stimulating hormone decreased 25.97 13.51 15 17226 1783 29555503
Parkinsonism 25.39 13.51 26 17215 7252 29550034
Product administration error 25.00 13.51 36 17205 14274 29543012
Post procedural haemorrhage 24.77 13.51 26 17215 7465 29549821
Neutropenia 24.75 13.51 146 17095 131565 29425721
Vertigo 24.55 13.51 45 17196 21816 29535470
Subileus 24.20 13.51 17 17224 2833 29554453
Toxic skin eruption 23.94 13.51 29 17212 9728 29547558
Altered state of consciousness 23.68 13.51 42 17199 19847 29537439
Soft tissue mass 23.32 13.51 10 17231 626 29556660
Diffuse large B-cell lymphoma recurrent 23.25 13.51 16 17225 2581 29554705
Melaena 23.02 13.51 54 17187 31122 29526164
Stool analysis abnormal 22.98 13.51 5 17236 27 29557259
Hyperlipasaemia 22.39 13.51 9 17232 478 29556808
Illusion 22.37 13.51 10 17231 692 29556594
Hypokalaemia 22.14 13.51 72 17169 50131 29507155
Purpura 21.94 13.51 27 17214 9205 29548081
Campylobacter gastroenteritis 21.79 13.51 10 17231 736 29556550
Febrile neutropenia 21.79 13.51 20 17221 112220 29445066
Incontinence 21.33 13.51 20 17221 5012 29552274
Dysuria 21.28 13.51 43 17198 22397 29534889
Dissociation 20.64 13.51 11 17230 1118 29556168
Hanging 20.49 13.51 6 17235 120 29557166
Capillary fragility 20.46 13.51 5 17236 48 29557238
Febrile bone marrow aplasia 19.94 13.51 23 17218 7328 29549958
Bradycardia 19.60 13.51 83 17158 65546 29491740
Normocytic anaemia 19.57 13.51 13 17228 1979 29555307
Hepatitis cholestatic 19.43 13.51 22 17219 6871 29550415
Steroid diabetes 18.92 13.51 12 17229 1689 29555597
Dizziness 18.91 13.51 181 17060 189503 29367783
Haemoglobinaemia 18.86 13.51 6 17235 160 29557126
Prostatomegaly 18.76 13.51 18 17223 4643 29552643
Hallucination 18.70 13.51 63 17178 44649 29512637
Vitamin B12 decreased 18.53 13.51 10 17231 1042 29556244
Hallucination, visual 18.25 13.51 32 17209 14983 29542303
Pelvic fracture 18.23 13.51 13 17228 2218 29555068
Hypernatraemia 18.20 13.51 22 17219 7364 29549922
Hypovolaemic shock 18.18 13.51 20 17221 6052 29551234
On and off phenomenon 17.54 13.51 12 17229 1916 29555370
Growth hormone deficiency 16.94 13.51 6 17235 224 29557062
Cardiac failure congestive 16.91 13.51 12 17229 76569 29480717
Anaemia 16.81 13.51 185 17056 200766 29356520
Tonic clonic movements 16.78 13.51 9 17232 926 29556360
Hepatitis 16.44 13.51 37 17204 20746 29536540
Angina pectoris 16.13 13.51 44 17197 27806 29529480
Hyponatraemia 16.08 13.51 80 17161 67553 29489733
Hyperkeratosis 15.83 13.51 14 17227 3255 29554031
Hyperkalaemia 15.59 13.51 74 17167 61318 29495968
Expired product administered 15.57 13.51 13 17228 2798 29554488
Presyncope 15.45 13.51 31 17210 16058 29541228
Death 15.27 13.51 127 17114 341957 29215329
Amaurosis fugax 15.19 13.51 7 17234 520 29556766
Cystitis interstitial 15.00 13.51 5 17236 155 29557131
Blood pressure decreased 14.74 13.51 59 17182 45418 29511868
Paramnesia 14.73 13.51 3 17238 11 29557275
Behaviour disorder 14.62 13.51 14 17227 3602 29553684
Ketonuria 14.55 13.51 7 17234 573 29556713
Hyperhidrosis 14.40 13.51 75 17166 64465 29492821
Dyspnoea at rest 14.06 13.51 13 17228 3201 29554085
Eczema 13.71 13.51 27 17214 13799 29543487
Pancreatitis acute 13.60 13.51 38 17203 24347 29532939

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 194.94 13.88 371 15261 448869 64034231
Confusional state 91.70 13.88 198 15434 260946 64222154
Drug interaction 87.94 13.88 238 15394 361845 64121255
Cholestasis 84.73 13.88 77 15555 44795 64438305
Orthostatic hypotension 83.97 13.88 78 15554 46660 64436440
Thrombocytopenia 78.87 13.88 170 15462 223631 64259469
Drug dispensed to wrong patient 77.20 13.88 18 15614 359 64482741
Antimicrobial susceptibility test resistant 76.80 13.88 17 15615 266 64482834
Syncope 76.47 13.88 137 15495 157498 64325602
Agranulocytosis 74.93 13.88 67 15565 38162 64444938
Hepatocellular injury 70.85 13.88 70 15562 45165 64437935
Fall 69.32 13.88 240 15392 416586 64066514
Hypotension 62.12 13.88 218 15414 380756 64102344
Urinary retention 57.24 13.88 65 15567 49136 64433964
Eosinophilia 56.09 13.88 57 15575 38019 64445081
Coma 55.66 13.88 86 15546 87529 64395571
Therapeutic response delayed 53.27 13.88 16 15616 866 64482234
Neutropenia 51.64 13.88 151 15481 239473 64243627
Wrong patient received product 48.96 13.88 22 15610 3740 64479360
Pemphigoid 47.73 13.88 33 15599 12953 64470147
Hallucination, visual 45.30 13.88 44 15588 27790 64455310
Staring 44.30 13.88 18 15614 2392 64480708
Wrong product administered 39.12 13.88 24 15608 7696 64475404
Disorganised speech 36.18 13.88 14 15618 1636 64481464
Hyperkalaemia 35.74 13.88 77 15555 101052 64382048
Cell death 35.34 13.88 18 15614 4036 64479064
Completed suicide 35.24 13.88 6 15626 224408 64258692
Pain 35.03 13.88 50 15582 553461 63929639
Daydreaming 33.49 13.88 11 15621 799 64482301
Altered state of consciousness 32.59 13.88 43 15589 37859 64445241
Minimum inhibitory concentration 31.74 13.88 6 15626 40 64483060
Petit mal epilepsy 31.68 13.88 18 15614 5014 64478086
Dermatitis exfoliative generalised 31.54 13.88 19 15613 5897 64477203
Brain stem haematoma 31.24 13.88 7 15625 116 64482984
Allergy to animal 30.99 13.88 11 15621 1010 64482090
Toxic skin eruption 30.47 13.88 30 15602 19254 64463846
Bradycardia 29.86 13.88 79 15553 118140 64364960
Parkinsonism 29.76 13.88 26 15606 14347 64468753
Melaena 29.12 13.88 49 15583 53499 64429601
Disorientation 28.93 13.88 50 15582 55778 64427322
Haematuria 28.55 13.88 52 15580 60419 64422681
Soft tissue mass 28.38 13.88 10 15622 899 64482201
Prostatomegaly 28.29 13.88 14 15618 2953 64480147
Toxicity to various agents 28.12 13.88 28 15604 363485 64119615
Perseveration 27.77 13.88 8 15624 374 64482726
Apraxia 27.49 13.88 13 15619 2482 64480618
Drug intolerance 27.45 13.88 6 15626 187986 64295114
Hepatitis cholestatic 27.23 13.88 23 15609 12132 64470968
Alopecia 26.97 13.88 4 15628 165686 64317414
Febrile bone marrow aplasia 26.67 13.88 22 15610 11233 64471867
Campylobacter gastroenteritis 26.38 13.88 10 15622 1106 64481994
Status epilepticus 25.83 13.88 29 15603 21634 64461466
Purpura 25.72 13.88 26 15606 17220 64465880
Headache 25.23 13.88 57 15575 529410 63953690
Rheumatoid arthritis 24.48 13.88 5 15627 164289 64318811
Prostate cancer 24.46 13.88 27 15605 19768 64463332
On and off phenomenon 24.36 13.88 12 15620 2507 64480593
Product dispensing error 24.29 13.88 21 15611 11429 64471671
Hypovolaemic shock 24.18 13.88 20 15612 10246 64472854
Hyponatraemia 24.17 13.88 85 15547 148254 64334846
Hallucination 24.10 13.88 54 15578 72734 64410366
Subileus 24.02 13.88 15 15617 4962 64478138
Tonic clonic movements 23.89 13.88 11 15621 1978 64481122
Steroid diabetes 23.71 13.88 12 15620 2654 64480446
Hyperlipasaemia 23.69 13.88 9 15623 1001 64482099
Blood thyroid stimulating hormone decreased 23.34 13.88 15 15617 5215 64477885
Nasal discomfort 23.33 13.88 14 15618 4314 64478786
Illusion 23.07 13.88 10 15622 1560 64481540
Behaviour disorder 22.94 13.88 14 15618 4448 64478652
Bicytopenia 22.92 13.88 13 15619 3609 64479491
Hepatitis 22.54 13.88 40 15592 45542 64437558
Infusion related reaction 22.54 13.88 6 15626 164461 64318639
Dehydration 21.75 13.88 107 15525 216656 64266444
Pancreatitis acute 21.70 13.88 38 15594 42817 64440283
Haemoglobinaemia 21.38 13.88 6 15626 255 64482845
Hanging 21.24 13.88 5 15627 104 64482996
Hypokalaemia 20.85 13.88 71 15561 121832 64361268
Product administration error 20.21 13.88 29 15603 27614 64455486
Swelling 19.87 13.88 7 15625 160211 64322889
Pneumonia aspiration 19.65 13.88 44 15588 59227 64423873
Growth hormone deficiency 19.62 13.88 6 15626 345 64482755
Dissociation 19.58 13.88 11 15621 3000 64480100
Incontinence 19.47 13.88 19 15613 12062 64471038
Normocytic anaemia 18.64 13.88 11 15621 3288 64479812
Treatment failure 18.60 13.88 3 15629 116813 64366287
Dysuria 18.39 13.88 35 15597 42022 64441078
Psychomotor hyperactivity 18.36 13.88 20 15612 14431 64468669
Amaurosis fugax 18.24 13.88 7 15625 800 64482300
Pulmonary interstitial emphysema syndrome 17.99 13.88 6 15626 457 64482643
Capillary fragility 17.97 13.88 5 15627 206 64482894
Hyperkeratosis 17.82 13.88 14 15618 6667 64476433
Nausea 17.62 13.88 115 15517 785685 63697415
Vertigo 17.57 13.88 42 15590 58969 64424131
Blood pressure decreased 17.27 13.88 53 15579 86146 64396954
Subdural haematoma 17.05 13.88 27 15605 28027 64455073
Dementia 16.99 13.88 23 15609 20743 64462357
Expired product administered 16.96 13.88 13 15619 5974 64477126
Gynaecomastia 16.90 13.88 13 15619 6003 64477097
Anaemia 16.58 13.88 152 15480 378528 64104572
Amyotrophy 16.55 13.88 6 15626 585 64482515
Disturbance in attention 16.52 13.88 33 15599 41041 64442059
Drug hypersensitivity 16.51 13.88 20 15612 237795 64245305
Gout 16.44 13.88 23 15609 21390 64461710
Presyncope 16.34 13.88 30 15602 35059 64448041
Dyspnoea at rest 16.32 13.88 13 15619 6316 64476784
Intraventricular haemorrhage 16.32 13.88 11 15621 4142 64478958
Therapeutic product effect decreased 16.20 13.88 4 15628 115347 64367753
Product storage error 16.17 13.88 18 15614 13300 64469800
Lichenoid keratosis 15.97 13.88 10 15622 3324 64479776
Cerebral haemorrhage 15.90 13.88 37 15595 51053 64432047
Hyperhidrosis 15.75 13.88 66 15566 124854 64358246
Oversensing 15.74 13.88 3 15629 21 64483079
Cardiovascular insufficiency 15.49 13.88 9 15623 2615 64480485
Pallor 15.41 13.88 31 15601 38750 64444350
Abdominal discomfort 15.31 13.88 13 15619 182309 64300791
Paramnesia 15.18 13.88 3 15629 26 64483074
Inferior vena cava dilatation 15.13 13.88 6 15626 748 64482352
Leukopenia 14.78 13.88 56 15576 101186 64381914
Lactic acidosis 14.45 13.88 40 15592 61370 64421730
Renal failure 14.34 13.88 84 15548 181604 64301496
Atrioventricular block 14.18 13.88 16 15616 11999 64471101
Atrioventricular block second degree 14.02 13.88 12 15620 6442 64476658
Cardio-respiratory arrest 14.01 13.88 54 15578 98339 64384761
Hypernatraemia 13.99 13.88 16 15616 12173 64470927

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G04CA01 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
Alpha-adrenoreceptor antagonists
ATC G04CA51 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
Alpha-adrenoreceptor antagonists
FDA MoA N0000000099 Adrenergic alpha-Antagonists
FDA EPC N0000175553 alpha-Adrenergic Blocker
MeSH PA D018663 Adrenergic Agents
MeSH PA D058668 Adrenergic alpha-1 Receptor Antagonists
MeSH PA D000317 Adrenergic alpha-Antagonists
MeSH PA D018674 Adrenergic Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D064804 Urological Agents
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:35674 antihypertensive drugs
CHEBI has role CHEBI:37890 alpha-adrenergic receptor blockaders

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Benign prostatic hyperplasia indication 266569009
Orthostatic hypotension contraindication 28651003
Torsades de pointes contraindication 31722008
Low blood pressure contraindication 45007003
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Cataract surgery contraindication 110473004
Prolonged QT interval contraindication 111975006
Angina pectoris contraindication 194828000
Micturition syncope contraindication 234168001
Disease of liver contraindication 235856003 DOID:409
Intraoperative floppy iris syndrome contraindication 418801006
Congenital long QT syndrome contraindication 442917000
Progressive Angina Pectoris contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.09 acidic
pKa2 7.22 Basic
pKa3 0.97 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Alpha-1A adrenergic receptor GPCR ANTAGONIST Ki 8.09 CHEMBL CHEMBL
Alpha-1D adrenergic receptor GPCR ANTAGONIST Ki 8.44 CHEMBL CHEMBL
Alpha-1B adrenergic receptor GPCR ANTAGONIST Ki 8.55 CHEMBL CHEMBL
Acetylcholinesterase Enzyme IC50 7.75 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.83 CHEMBL
Alpha-1D adrenergic receptor GPCR Ki 8.46 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 7.64 CHEMBL

External reference:

IDSource
4021396 VUID
N0000148814 NUI
D01692 KEGG_DRUG
81403-68-1 SECONDARY_CAS_RN
17300 RXNORM
C0051150 UMLSCUI
CHEBI:51141 CHEBI
CHEMBL709 ChEMBL_ID
DB00346 DRUGBANK_ID
CHEMBL1723 ChEMBL_ID
C047638 MESH_SUPPLEMENTAL_RECORD_UI
2092 PUBCHEM_CID
7109 IUPHAR_LIGAND_ID
5357 INN_ID
90347YTW5F UNII
16517 MMSL
184661 MMSL
43057 MMSL
47077 MMSL
d04797 MMSL
005431 NDDF
005432 NDDF
4021396 VANDF
349912006 SNOMEDCT_US
395725004 SNOMEDCT_US
395954002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Alfuzosin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0440-5000 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 24 sections
ALFUZOSIN HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 13668-021 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 25 sections
Uroxatral HUMAN PRESCRIPTION DRUG LABEL 1 16590-279 TABLET, EXTENDED RELEASE 10 mg ORAL NDA 11 sections
Alfuzosin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 29300-155 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 17 sections
Alfuzosin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 29300-155 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 17 sections
Alfuzosin Hydrochlorideextended release HUMAN PRESCRIPTION DRUG LABEL 1 31722-302 TABLET 10 mg ORAL ANDA 24 sections
Alfuzosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 33261-994 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 25 sections
Alfuzosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 43353-746 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
Alfuzosin hydrochloride Human Prescription Drug Label 1 43353-945 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 24 sections
Alfuzosin Hydrochloride Human Prescription Drug Label 1 47335-956 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
Uroxatral HUMAN PRESCRIPTION DRUG LABEL 1 54868-5046 TABLET, EXTENDED RELEASE 10 mg ORAL NDA 28 sections
Alfuzosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 54868-6329 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
Alfuzosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 55648-738 TABLET 10 mg ORAL ANDA 25 sections
Alfuzosin Hydrochloride Human Prescription Drug Label 1 57237-114 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
Uroxatral Human Prescription Drug Label 1 59212-200 TABLET, EXTENDED RELEASE 10 mg ORAL NDA 27 sections
ALFUZOSIN HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 61919-349 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 18 sections
Alfuzosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 63629-2353 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
Alfuzosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 63629-2353 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
Alfuzosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 63629-2354 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
Alfuzosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 63629-2354 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
Alfuzosin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 63629-7907 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 17 sections
Alfuzosin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 63629-7907 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 17 sections
Alfuzosin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 63629-9155 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 17 sections
Alfuzosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 63629-9295 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
Alfuzosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 64679-738 TABLET 10 mg ORAL ANDA 24 sections
Alfuzosin Hydrochloride Human Prescription Drug Label 1 65862-249 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
Alfuzosin Hydrochlorideextended release HUMAN PRESCRIPTION DRUG LABEL 1 69097-844 TABLET 10 mg ORAL ANDA 25 sections
Alfuzosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 70934-306 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
Alfuzosin Hydrochlorideextended release HUMAN PRESCRIPTION DRUG LABEL 1 70934-961 TABLET 10 mg ORAL ANDA 25 sections
Alfuzosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 71335-1529 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections